N6-[2-(4-Aminophenyl)ethyl]adenosine

Research use only, not for human use.

A non-selective agonist of Adenosine A3 receptor; has a high affinity for the adenosine A1 and A3 receptors.

A non-selective agonist of Adenosine A3 receptor; has a high affinity for the adenosine A1 and A3 receptors; APNEA (0.0039-1 mg/kg) enhances the protective activity of carbamazepine; dose-dependently increase the sustained (4 min) Ca2+ influx into rat cortical synaptosomes.

APNEA (N6-[2-(4-Aminophenyl)ethyl]adenosine) is a non-selective agonist of the adenosine A3 receptors, at the subprotective dose of 1 mg/kg against electroconvulsions, significantly potentiates the anticonvulsive action of phenobarbital, diphenylhydantoin and valproate against maximal electroshock, being ineffective at lower doses. APNEA (0.0039-1 mg/kg) also enhances the protective activity of carbamazepine. APNEA at low doses potentiates the protective activity of Carbamazepine most likely through the A subtype of adenosine receptors. At higher doses, APNEA seems to enhance the anticonvulsive effect of other antiepileptics via adenosine A1 receptors.

APNEA (N6-[2-(4-Aminophenyl)ethyl]adenosine; 2-4 mg/kg) has no significant effect on seizure parameters (seizure severity, seizure duration and afterdischarge duration) in amygdala-kindled rats. N6-[2-(4-Aminophenyl)ethyl]adenosine is combined with antiepileptic drugs administered at doses ineffective in fully kindled rats.

APNEA

Apoptosis

Adenosine Receptor

Adenosine Receptor

Neurological Disease

——

89705-21-5

386.4051

C18H22N6O4

>98% (HPLC)

10 mM in DMSO

C1=CC(=CC=C1CCNC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N

Adenosine, N-[2-(4-aminophenyl)ethyl]-

(-20℃)

With Ice Pack

≥ 2 years